News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

APP Pharmaceuticals Announces Trading Information on NASDAQ of Contingent Value Rights Associated with the Acquisition by Fresenius SE


9/11/2008 8:31:56 AM

SCHAUMBURG, Ill.--(BUSINESS WIRE)--APP Pharmaceuticals, Inc., formerly traded on the NASDAQ Capital Market under the symbol APPX, today announced that the NASDAQ Global Market has accepted for listing the Contingent Value Rights (CVRs) related to the acquisition of APP by Fresenius Kabi, a business segment of Fresenius SE. The CVRs will trade under the symbol “APCVZ” beginning on Thursday, September 11, 2008.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES